A common virus may play a major role in causing a painful disease of immune cells that attacks children’s bones, according to a new study. The research may eventually lead to an easier diagnosis and to more effective treatments of the disease, Langerhans cell histiocytosis. Researchers found evidence of the virus, human herpesvirus 6 (HHV-6) in the tissues of 25 of 35 children with Langerhans cell histiocytosis (LCH), compared to virus detected in only five of 19 children without LCH.From the Children’s Hospital of Philadelphia :Common virus may contribute to uncommon bone disease in children
A common virus may play a major role in causing a painful disease of immune cells that attacks children’s bones, according to a new study. The research may eventually lead to an easier diagnosis and to more effective treatments of the disease, Langerhans cell histiocytosis.
Researchers found evidence of the virus, human herpesvirus 6 (HHV-6) in the tissues of 25 of 35 children with Langerhans cell histiocytosis (LCH), compared to virus detected in only five of 19 children without LCH. The research team, led by John P. Dormans, M.D., director of Orthopaedic Surgery at The Children’s Hospital of Philadelphia, published its findings in the January/February issue of the Journal of Pediatric Orthopaedics.
Langerhans cells, found in the blood, play an active role in the immune system. An uncontrolled excess of Langerhans cells leads to LCH, with effects that range from a limited, spontaneously resolving illness to a chronic, life-threatening disease involving multiple organ systems. Although rare, occurring in approximately five children per million, LCH most commonly strikes bone, causing painful lesions or fractures.
“LCH is called the ‘great imitator’ because it resembles particular bone cancers,” said Dr. Dormans. “Fortunately, most children survive the disease these days.” Most bone lesions resolve on their own without treatment. In other cases, surgeons successfully treat the disease by removing the abnormal area of bone.
However, successful treatment may elude physicians when LCH is chronic and affects multiple systems. Chemotherapy may succeed, at least temporarily, but only for 50 to 60 percent of patients. The cause of LCH remains unknown, and the Children’s Hospital researchers investigated its origins, with the goal of advancing treatments.
“It’s important to define whether LCH is primarily a tumor-like process or a reactive process, that is, one in which the immune system reacts to an infection or other insult,” said Michael P. Glotzbecker, of the University of Pennsylvania School of Medicine, and the first author of the study. “Our research strengthens the case for a reaction to infection. Understanding the origin of the disease may help redefine the best treatment.”
Previous researchers had proposed a role for HHV-6 infection in LCH, but the evidence was indirect, or was questioned on grounds of possible contamination. The current study was the first to identify the virus in the cytoplasm of immune cells called lymphocytes within LCH tissues. “Our findings suggest that after the HHV-6 virus infects lymphocytes, the body mounts an abnormal immune response resulting in the overproduction of Langerhans cells seen in LCH,” said Mr. Glotzbecker. The researchers confirmed the presence of the virus with in situ hybridization, a testing technique.
The virus, HHV-6, is extremely common in children and adults, but usually is cleared out of the body or neutralized by a normally functioning immune system. In fact, the researchers found evidence of the virus in 5 of 18 tissue samples from children without LCH. “Because HHV-6 infection is so prevalent, but so few children get LCH, our results suggest that the virus interacts with some underlying predisposition to the disease,” said Dr. Dormans.
“We don’t know what may cause a predisposition to this disease,” continued Dr. Dormans, “but rethinking the cause of LCH may ultimately shift treatment away from chemotherapy toward antiviral treatments or approaches that modify the immune system.” Much further research is necessary, he added, but in addition to guiding treatment, future research may lead to a simple blood test to diagnose the disease. “Such a test would be less invasive and certainly less painful for children than the tissue biopsy that we now must perform to diagnose LCH.”